Navigation Links
The Renal Anemia Market Shows Signs of Stabilization but Changes are Occurring in the Bone and Mineral Metabolism Market
Date:10/27/2010

EXTON, Pa., Oct. 27 /PRNewswire/ -- BioTrends Research Group, Inc. released two syndicated Nephrology TreatmentTrends® publications (TreatmentTrends®: US Nephrology Q310 and TreatmentTrends®: Renal Dietitians 2010). These reports provide information gleaned from on-line surveys with 200 nephrologists and 205 renal dietitians and capture insight into attitudes, perceptions and self-reported prescribing behavior with a focus on renal anemia and bone and mineral metabolism in chronic kidney disease and dialysis.  

In the renal anemia market, use of erythropoietin stimulating agents (ESAs) in patients with chronic kidney disease, not on dialysis (CKD-ND) is showing signs of stabilization. Although use is still far lower than it was just a few years ago, for the first time in almost a year, the percent of Stage 4 CKD-ND patients on ESAs is trending up instead of down. While not a statistically significant change, use of Centocor Ortho-Biotech's Procrit is lower than in prior quarters, and monthly contact rates for Procrit representatives are significantly lower than last year and than monthly contact rates for Amgen's Aranesp. Procrit also seems to be losing a competitive advantage on a number of attributes it once "owned". Despite prior projections of increased use of intravenous (IV) iron, use has remained steady as have the percent of nephrologists who report stocking and administering IV iron in their office. Use of the newest IV iron agent, AMAG's Feraheme, is showing signs of a plateau; for the third quarter in a row, Feraheme share has remained relatively flat among IV iron treated CKD-ND patients. Moreover, the percent of nephrologists reporting use of Feraheme has not changed.

There have been some major changes in the bone and mineral metabolism market, particularly as it relates to parathyroid hormone (PTH) modifiers. The majority of both nephrologists and renal dietitians are aware that DaVita, one of the largest dialysis providers, has changed from Abbott's Zemplar to Genzyme's Hectorol as its formulary product and that it has expanded its PTH target range. Despite potential preferences for one agent over another or opposition to the formulary change, very few nephrologists or renal dietitians expect to complete non-formulary requests for Zemplar. The majority of renal dietitians expect their use of active vitamin D and Amgen's Sensipar will decrease due to the new PTH range, but alternatively, Sensipar may benefit from the upcoming dialysis bundled payment system. In fact, for the second quarter in a row, nephrologists report that Sensipar use in hemodialysis patients is at higher levels than it has been in recent quarters. In terms of phosphate binders, use in Stage 4 CKD-ND patients continues to be lower than it was last year, although brand dynamics have remained relatively unchanged.  

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Sharon Funk404-223-2963sfunk@bio-trends.comDecision Resources, Inc.Christopher Comfort781-993-2597ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
5. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
6. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
7. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
8. Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
9. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
10. PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):